Loading...
Please wait, while we are loading the content...
Similar Documents
Inflammation, but not hypoxia, mediated HIF-1α activation depends on COX-2
| Content Provider | Scilit |
|---|---|
| Author | O'Brien, David R. Stasinopoulos, Ioannis Bhujwalla, Zaver M. |
| Copyright Year | 2009 |
| Description | The COX pathway has been a target for pharmaceutical intervention in diseases with a high inflammatory component ranging from asthma and Alzheimer's to arthritis and cancer. A major transcriptional promoter of the malignant phenotype, HIF-1α, has been observed to be regulated by the COX-2 product PGE2. Here we show that HIF-1α protein significantly accumulated in human breast cancer MDA-MB-231 cells in response to the pro-inflammatory cytokine IL-1β, but not in COX-2-silenced MDA-MB-231 cells. In contrast HIF-1α expression could be detected in COX-2-silenced cells in response to the hypoxia-mimetic agent CoCl2 and hypoxia. Gene expression profiling in COX-2-containing and COX-2-silenced cells showed that the hypoxia-induced transcriptional response is largely unaffected by COX-2 silencing. These data suggest that the profound effects of COX-2 silencing on inhibiting invasion, tumor growth, and metastasis from MDA-MB-231 cells are dependent on the induction of IL-1β-dependent COX-2 and HIF-1α but are independent of hypoxia. |
| Related Links | https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.1.7079?needAccess=true https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058789/pdf |
| Ending Page | 35 |
| Page Count | 5 |
| Starting Page | 31 |
| ISSN | 15384047 |
| e-ISSN | 15558576 |
| DOI | 10.4161/cbt.8.1.7079 |
| Journal | Cancer Biology & Therapy |
| Issue Number | 1 |
| Volume Number | 8 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2009-01-01 |
| Access Restriction | Open |
| Subject Keyword | Biochemistry and Molecular Biology Breast Cancer Inflammation Cox-2 Cox-2-silencing Hypoxia Hif-1α |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Pharmacology Molecular Medicine Oncology |